Real-World Studies
Similar Survival Across Second-Line Regimens in Advanced Biliary Tract Cancer
Chao et alThe oncologist

In a real-world comparative effectiveness study of adults with advanced biliary tract cancer (BTC) who progressed on first-line gemcitabine plus cisplatin, second-line chemotherapy with FOLFOX, FOLFIRI, or CapOx yielded comparable survival outcomes. Investigators identified patients treated between January 2010 and July 2025 using the TriNetX Global Collaborative Network, excluding those who subsequently received molecularly targeted agents.
The original cohort comprised 825 patients treated with FOLFOX, 184 with FOLFIRI, and 149 with CapOx. Following 1:1 propensity score matching, the FOLFOX versus FOLFIRI cohort evaluated 182 matched patients per group, and the FOLFOX versus CapOx cohort evaluated 149 matched patients per group.
Median overall survival was 5.7 months for FOLFOX versus 5.8 months for FOLFIRI (P = .958), and 5.7 months for FOLFOX versus 5.8 months for CapOx (P = .803). Overall adverse event profiles were comparable across regimens. FOLFOX was associated with lower rates of neutropenia but higher rates of thrombocytopenia than FOLFIRI, whereas FOLFOX and CapOx demonstrated similar toxicity despite modest differences in anemia and thrombocytopenia. The authors concluded that these findings support tailoring regimen selection to individual patient characteristics and toxicity profiles.
Key Takeaways
- In propensity score-matched cohorts, median overall survival was comparable between FOLFOX and FOLFIRI (5.7 vs 5.8 months, P = .958) and between FOLFOX and CapOx (5.7 vs 5.8 months, P = .803).
- Safety profiles showed FOLFOX was associated with lower rates of neutropenia but higher rates of thrombocytopenia compared with FOLFIRI, while FOLFOX and CapOx exhibited similar overall toxicity with modest differences in anemia and thrombocytopenia.
Read the original sourceThe oncologist
